证券代码：002622 证券简称：皓宸医疗 公告编号：2025-032 皓宸医疗科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）于2025年12月12日召开第 五届董事会第二十六次临时会议审议通过了《关于续聘会计师事务所的议案》， 拟续聘众华会计师事务所（特殊普通合伙）作为公司2025年度审计机构，现将相 关情况公告如下： 一、拟续聘会计师事务所事项的情况说明 本公司拟续聘众华会计师事务所（特殊普通合伙）担任2025年度审计机构， 该所为本公司2024年度审计机构，其在担任公司审计机构期间，遵循了《中国注 册会计师独立审计准则》，勤勉尽责，坚持独立、客观、公正的审计准则，公允 合理地发表了独立审计意见，不存在违反《中国注册会计师职业道德守则》对独 立性要求的情形。为保证审计工作的连续性，公司拟续聘众华会计师事务所（特 殊普通合伙）担任2025年度审计机构，续聘期一年，公司董事会提请股东会授权 公司管理层根据公司审计业务的实际情况与众华会计师事务所协商确定2025年 度相关审 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-033 皓宸医疗科技股份有限公司 关于召开 2025 年第二次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第二次临时股东会 （3）本公司聘请的律师。 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、 规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 月 29 日 14:50 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 12 月 29 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 12 月 29 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-031 皓宸医疗科技股份有限公司 第五届董事会第二十六次临时会议决议公告 表决情况：同意 7 票，反对 0 票，弃权 0 票； （2）审议通过《董事会提名委员会议事规则》 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第二十六次 临时会议于 2025 年 12 月 12 日上午 11:00 以现场结合通讯表决的方式召开。本 次会议已于 2025 年 12 月 9 日以电话、电子邮件等方式通知了各位董事。本次会 议由董事长陆璐女士主持，会议应出席董事 7 名，实际出席董事 7 名。此次会议 的召集、召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关 法律、法规的规定，合法有效。经与会董事认真审议并表决，通过了以下议案： 一、逐项审议通过《关于修订公司部分内部制度的议案》 为进一步完善公司治理体系，提升公司规范运作水平，根据《公司法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第1号— —主板上市公司规范运作 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 来源：@华夏时报微博 华夏时报记者 张玫 北京报道 源起"中植系"债务危机 皓宸医疗与"中植系"（以中植企业集团为核心的资本体系）曾有过为期三年（2020年至2023年）的从属 关系，但自2023年下半年起，因"中植系"自身陷入严重危机，双方的合作破裂，最终在2025年11月经法 院判决后彻底脱离关系。 11月14日，皓宸医疗发布公告，披露了公司控制权发生重大变更的细节。根据法院判决，公司第一大股 东的执行事务合伙人已解除了与北京首拓融汇的投资合作协议。 由于合作协议解除，公司控股股东汇垠日丰持有的23.81%股份对应的表决权控制方发生了变更，公司 自此进入"无实际控制人"状态。 事情始末可追溯至2020年2月，皓宸医疗第一大股东汇垠日丰的执行事务合伙人汇垠澳丰与"中植系"旗 下北京首拓融汇投资有限公司（下称"北京首拓融汇"）签署了《合作协议》。根据协议，汇垠日丰持有 的皓宸医疗23.81%股份对应的表决权，需根据北京首拓融汇的意见行使。至此，"中植系"通过协议安 排，实现对上市公司的实际控制。公司实控人变更为中植集团创始人解直锟。 双方约定的一个关键终止条件 ...

Core Viewpoint - The report highlights a significant delay in the disclosure of control changes at Haocen Medical Technology Co., Ltd., resulting in nearly a quarter of its shares and voting rights being in a regulatory blind spot for six months [2][4]. Group 1: Control Change and Legal Disputes - Haocen Medical's largest shareholder, Huayin Rifen, faced a control change due to the termination of an investment cooperation agreement with Beijing Shoutuo Ronghui, leading to a "no actual controller" status for the company [4][5]. - The relationship between Haocen Medical and the "Zhongzhi System" ended after a three-year association, primarily due to the latter's severe debt crisis [3][4]. - The court's final ruling on April 29, 2025, confirmed the validity of the termination of the cooperation agreement, which directly caused the change in control at Haocen Medical [5][6]. Group 2: Information Disclosure Issues - The disclosure of the control change was significantly delayed, with Huayin Rifen only formally disclosing the detailed report on November 15, 2025, despite the court ruling occurring months earlier [6]. - The delay in information disclosure has raised concerns about regulatory compliance and transparency within the company [6]. Group 3: Financial Performance and Risks - Haocen Medical has reported continuous losses from 2020 to 2024, with cumulative losses exceeding 700 million yuan, and a significant decline in revenue in the first half of 2025 [8][9]. - The company's main revenue source, a 51% stake in its subsidiary Delun Medical, has been judicially frozen, severely impacting its cash flow [9]. - As of mid-2025, the company faced substantial short-term debt pressures, with short-term borrowings amounting to 191 million yuan [8].

Market Overview - The medical services sector increased by 0.56% on November 25, with ST Zhongzhu leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Medical Services - ST Zhongzhu (600568) closed at 2.57, up 4.90% with a trading volume of 53,900 shares and a turnover of 13.85 million yuan [1] - Chengda Pharmaceutical (301201) closed at 47.78, up 2.97% with a trading volume of 112,700 shares and a turnover of 540 million yuan [1] - Boji Pharmaceutical (300404) closed at 10.10, up 2.75% with a trading volume of 108,600 shares and a turnover of 10.9 million yuan [1] Top Losers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 18.75, down 0.85% with a trading volume of 181,100 shares and a turnover of 343 million yuan [2] - Tongce Medical (600763) closed at 41.95, down 0.66% with a trading volume of 49,600 shares and a turnover of 210 million yuan [2] - Yingkang Life (300143) closed at 10.12, down 0.49% with a trading volume of 44,700 shares and a turnover of 4.56 million yuan [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 113 million yuan from institutional investors, while retail investors saw a net inflow of 30.37 million yuan [2][3] - Major stocks like WuXi AppTec (603259) had a net inflow of 67.13 million yuan from institutional investors, while Sunshine Nuohua (688621) saw a net outflow of 2.29 million yuan from retail investors [3] Summary of Individual Stock Performance - Sunshine Nuohua (688621) had a net inflow of 38.24 million yuan from institutional investors, but a net outflow of 3.59 million yuan from retail investors [3] - Chengda Pharmaceutical (301201) also saw a significant net inflow of 36.45 million yuan from institutional investors, with a net outflow of 13.58 million yuan from retail investors [3] - New Mileage (002219) had a net inflow of 14.15 million yuan from institutional investors, while retail investors experienced a net outflow of 6.70 million yuan [3]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

Core Viewpoint - The recent announcement by Haocen Medical indicates a change in control, leading to a state of no actual controller, amidst ongoing financial struggles and legal disputes. Group 1: Control Change - Haocen Medical's largest shareholder, Guangzhou Huiyin Rifen Investment Partnership, has undergone a control change, resulting in the company having no actual controller [1][3] - The control change stems from a long-standing cooperation dispute between Huiyin Aofeng and Beijing Shoutuo Ronghui, which was confirmed by a court ruling [2][3] Group 2: Financial Performance - Haocen Medical has reported continuous losses for five consecutive years, with cumulative losses exceeding 700 million yuan from 2020 to 2024 [6] - In the first three quarters of 2025, the company achieved a revenue of 527 million yuan, a year-on-year decrease of 17.0%, with a net profit loss of 26.41 million yuan, a decline of 295.7% [7] Group 3: Business Challenges - The decline in the core dental medical service business is a significant factor in the company's revenue drop, with this segment accounting for 91.98% of total revenue and experiencing a 17.39% year-on-year decrease in the first half of 2025 [8] - Haocen Medical's subsidiary, Delun Medical, has faced a court-ordered freeze on 51% of its shares due to a creditor dispute, which poses risks to the company's operations [9] Group 4: Attempts at Recovery - The company has made unsuccessful attempts to recover financially, including failed auctions of bank shares and attempts to secure loans, which have not alleviated its financial strain [10]

Core Viewpoint - Haocen Medical (002622) has undergone a change in its actual controller due to the termination of a cooperation agreement, resulting in the company becoming a state without an actual controller. This change does not affect the company's normal operations or harm the interests of minority shareholders [1]. Group 1: Stock Performance - As of November 17, 2025, Haocen Medical closed at 3.59 yuan, down 0.83% from the previous trading day, with a total market capitalization of 3.016 billion yuan [1]. - The stock opened at 3.61 yuan, reached a high of 3.64 yuan, and a low of 3.52 yuan, with a trading volume of 90.3627 million yuan and a turnover rate of 3.02% [1]. Group 2: Corporate Announcement - Haocen Medical announced a change in equity and actual controller, stating that the first major shareholder, Huayin Rifeng, has terminated its cooperation agreement with Beijing Shoutuo Ronghui, leading to the change [1]. - The court's effective judgment has confirmed the termination of the cooperation agreement, resulting in Huayin Aofeng controlling the voting rights of 23.81% of the company's shares [1]. - Huayin Aofeng has no actual controller, which means Haocen Medical is now in a state without an actual controller [1].

Policy Developments - The National Health Commission's Director Lei Haichao emphasized the importance of planning for the "14th Five-Year Plan" to accelerate the construction of a healthy China and promote high-quality population development [2] - Key tasks include optimizing the function and layout of medical institutions, implementing strong foundational healthcare projects, and enhancing public health capabilities [2] Pharmaceutical Industry Updates - Bai Cheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a drug for treating acute ischemic stroke, with no current approvals for this product domestically or internationally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar drug for HER2-positive breast cancer, with applications for registration in China and Europe also accepted [6] Market Movements - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares through an inquiry-based transfer due to operational needs [8][9] - Enwei Pharmaceutical announced a 20 million yuan investment to establish a fund focused on healthcare and technology sectors, with a total fund size of 201 million yuan [10] Major Industry Events - Guangxi's pharmaceutical exports reached a record high, with a year-on-year increase of 27.23% in the first three quarters of the year [13] - Samsung Medical's subsidiary is a candidate for a procurement project with an estimated value of 168 million yuan, which could positively impact the company's performance [14] Corporate Governance Changes - Haocen Medical announced a change in control, with no single controlling party, following the termination of a cooperation agreement [16] - Yifeng Pharmacy's executives plan to reduce their holdings by a total of 0.0176% of shares due to personal financial needs [17]